These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

542 related articles for article (PubMed ID: 31745331)

  • 1. The global preclinical antibacterial pipeline.
    Theuretzbacher U; Outterson K; Engel A; Karlén A
    Nat Rev Microbiol; 2020 May; 18(5):275-285. PubMed ID: 31745331
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A novel pre-clinical antibacterial pipeline database.
    Paulin S; Alm RA; Beyer P
    PLoS One; 2020; 15(7):e0236604. PubMed ID: 32722726
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analysis of the Clinical Pipeline of Treatments for Drug-Resistant Bacterial Infections: Despite Progress, More Action Is Needed.
    Butler MS; Gigante V; Sati H; Paulin S; Al-Sulaiman L; Rex JH; Fernandes P; Arias CA; Paul M; Thwaites GE; Czaplewski L; Alm RA; Lienhardt C; Spigelman M; Silver LL; Ohmagari N; Kozlov R; Harbarth S; Beyer P
    Antimicrob Agents Chemother; 2022 Mar; 66(3):e0199121. PubMed ID: 35007139
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America.
    Boucher HW; Talbot GH; Bradley JS; Edwards JE; Gilbert D; Rice LB; Scheld M; Spellberg B; Bartlett J
    Clin Infect Dis; 2009 Jan; 48(1):1-12. PubMed ID: 19035777
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A call for antibiotic alternatives research.
    Stanton TB
    Trends Microbiol; 2013 Mar; 21(3):111-3. PubMed ID: 23473628
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multidrug-resistant gram-negative organisms: a review of recently approved antibiotics and novel pipeline agents.
    Provenzani A; Hospodar AR; Meyer AL; Leonardi Vinci D; Hwang EY; Butrus CM; Polidori P
    Int J Clin Pharm; 2020 Aug; 42(4):1016-1025. PubMed ID: 32638294
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Newer antibacterial drugs for a new century.
    Devasahayam G; Scheld WM; Hoffman PS
    Expert Opin Investig Drugs; 2010 Feb; 19(2):215-34. PubMed ID: 20053150
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Challenges of antibacterial discovery revisited.
    Gwynn MN; Portnoy A; Rittenhouse SF; Payne DJ
    Ann N Y Acad Sci; 2010 Dec; 1213():5-19. PubMed ID: 21058956
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antibacterial research and development in the 21(st) Century--an industry perspective of the challenges.
    Thomson CJ; Power E; Ruebsamen-Waigmann H; Labischinski H
    Curr Opin Microbiol; 2004 Oct; 7(5):445-50. PubMed ID: 15451498
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current landscape in the discovery of novel antibacterial agents.
    Vila J; Moreno-Morales J; Ballesté-Delpierre C
    Clin Microbiol Infect; 2020 May; 26(5):596-603. PubMed ID: 31574341
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design and Discovery of New Antibacterial Agents: Advances, Perspectives, Challenges.
    Jampilek J
    Curr Med Chem; 2018; 25(38):4972-5006. PubMed ID: 28925868
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Emerging novel and antimicrobial-resistant respiratory tract infections: new drug development and therapeutic options.
    Zumla A; Memish ZA; Maeurer M; Bates M; Mwaba P; Al-Tawfiq JA; Denning DW; Hayden FG; Hui DS
    Lancet Infect Dis; 2014 Nov; 14(11):1136-1149. PubMed ID: 25189352
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ESKAPEing the labyrinth of antibacterial discovery.
    Tommasi R; Brown DG; Walkup GK; Manchester JI; Miller AA
    Nat Rev Drug Discov; 2015 Aug; 14(8):529-42. PubMed ID: 26139286
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The 2012 Garrod lecture: discovery of antibacterial drugs in the 21st century.
    Chopra I
    J Antimicrob Chemother; 2013 Mar; 68(3):496-505. PubMed ID: 23134656
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Different drugs for bad bugs: antivirulence strategies in the age of antibiotic resistance.
    Dickey SW; Cheung GYC; Otto M
    Nat Rev Drug Discov; 2017 Jul; 16(7):457-471. PubMed ID: 28337021
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Better living through chemistry: Addressing emerging antibiotic resistance.
    Coussens NP; Molinaro AL; Culbertson KJ; Peryea T; Zahoránszky-Köhalmi G; Hall MD; Daines DA
    Exp Biol Med (Maywood); 2018 Mar; 243(6):538-553. PubMed ID: 29409348
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fighting antibiotic resistance-strategies and (pre)clinical developments to find new antibacterials.
    Walesch S; Birkelbach J; Jézéquel G; Haeckl FPJ; Hegemann JD; Hesterkamp T; Hirsch AKH; Hammann P; Müller R
    EMBO Rep; 2023 Jan; 24(1):e56033. PubMed ID: 36533629
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antibiotics in the clinical pipeline as of December 2022.
    Butler MS; Henderson IR; Capon RJ; Blaskovich MAT
    J Antibiot (Tokyo); 2023 Aug; 76(8):431-473. PubMed ID: 37291465
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The CARB-X Portfolio of Nontraditional Antibacterial Products.
    Duffy EM; Buurman ET; Chiang SL; Cohen NR; Uria-Nickelsen M; Alm RA
    ACS Infect Dis; 2021 Aug; 7(8):2043-2049. PubMed ID: 34346202
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Infections by multidrug-resistant Gram-negative Bacteria: What's new in our arsenal and what's in the pipeline?
    Koulenti D; Song A; Ellingboe A; Abdul-Aziz MH; Harris P; Gavey E; Lipman J
    Int J Antimicrob Agents; 2019 Mar; 53(3):211-224. PubMed ID: 30394301
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.